Loading
A phase 1/2 trial of AK112 in biliary tract cancer, run by Akeso, now recruiting.
A Study of AK130 in Combination With AK112 for the Treatment of Advanced Biliary Tract Cancer is a phase 1/2 interventional study registered as NCT06938321 by Akeso, with 135 participants planned, started 2025-04-30 and due to reach its primary completion in 2027-05. Interventions recorded: AK112 and AK130.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Akeso and the tag pipeline.
Shares Akeso and the tag pipeline.
Shares Biliary tract cancer (cholangiocarcinoma) and the tag pipeline.
Shares Akeso and the tag pipeline.
Shares Biliary tract cancer (cholangiocarcinoma) and the tag pipeline.
Shares Biliary tract cancer (cholangiocarcinoma) and the tag pipeline.
Shares Akeso, Biliary tract cancer (cholangiocarcinoma) and the tag pipeline.
Shares Akeso and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/